• 研究室概要
• 主要研究テーマ
• スタッフ
• 主な研究実績
• 共同開発・研究
• 主な研究費取得状況

連携大学院である生理活性物質制御学分野は、国立病院機構鹿児島医療センターで活動しています。
神経体液性因子の代表としてノルアドレナリンなどの交感神経由来の物質、レニン・アンジオテンシン・アルドステロン系、エンドセリン、心房性ナトリウム利尿ペプチド(ANP)、脳性ナトリウム利尿ペプチド(BNP)などの利尿ペプチドファミリー、インターロイキン、カーディオトロフィン-1などがあります。生理活性物質制御分野では、これらの神経体液性因子の循環器疾患における病態生理学的役割を解析しています。

研究室概要

分野サイト

連絡先

主要研究テーマ

スタッフ

鹿児島医療センター臨床研究部長

主な研究実績

城ヶ崎倫久

1. Umebashi K, Tokito A, Yamamoto M, Jougasaki M.
   Interleukin-33 induces interleukin-8 expression via JNK/c-Jun/AP-1 pathway in human umbilical vein endothelial cells.
   PLoS One; 13(1): e0191659, 2018.
2. Yamamoto M, Umebashi K, Tokito A, Imamura J, Jougasaki M.
   Interleukin-33 induces growth-regulated oncogene-α expression and secretion in human umbilical vein endothelial cells.
   Am J Physiol Regul Integr Comp Physiol; 313(3): R272-R279, 2017.
3. Tokito A, Jougasaki M.
   Matrix Metalloproteinases in Non-Neoplastic Disorders.
   Int J Mol Sci; 17(7), 2016.
4. Shimokawahara H, Jougasaki M, Setoguchi M, Ichiki T, Sonoda M, Nuruki N, Nakashima H, Murohara T, Tsubouchi H.:
   Relationship between vascular endothelial growth factor and left ventricular dimension in patients with acute myocardial infarction. J Cardiol; 64: 360-305, 2014.
5. Tokito A, Jougasaki M, Ichiki T, Hamasaki S.:
   Cardiotrophin-1 induces matrix metalloproteinase-1 in human aortic endothelial cells. PLoS One. 2013 Jul 23; 8(7): 68801.
6. Jougasaki M.:
   Cardiotrophin-1 in cardiovascular regulation. Adv Clin Chem 52: 41-76, 2010.
7. Jougasaki M, Ichiki T, Takenoshita Y, Setoguchi M.:
   Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells. Br J Pharmacol 159: 1294-1303, 2010.
8. Ichiki T, Jougasaki M, Setoguchi M, Imamura J, Nakashima H, Matsuoka T, Sonoda M, Nakamura K, Minagoe S, Tei C.:
   Cardiotrophin-1 stimulates intercellular adhesion molecule-1 and monocyte chemoattractant protein-1 in human aortic endothelial cells. Am J Physiol Heart Circ Physiol 294(2): H750-H763, 2008.
9. Jougasaki M, Leskinen H, Larsen AM, Luchner A, Cataliotti A, Tachibana I, Burnett JC Jr.:
   Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure. Peptides 24: 889-892, 2003.
10. Jougasaki M, Leskinen H, Larsen AM, Cataliotti A, Chen HH, Burnett JC Jr.:
    Leukemia Inhibitory Factor Is Augmented in the Heart in Experimental Heart Failure. Eur J Heart fail 5: 137-145, 2003.
11. Jougasaki M, Larsen AM, Cataliotti A, Christiansen DC, Burnett JC Jr.:
    Cardiotrophin-1 stimulates endothelin-1 via Gp130 in vascular endothelial cells. Peptides 23: 1441-1447, 2002.
12. Jougasaki M, Grantham JA, Redfield MM, Burnett JC Jr.:
    Regulation of cardiac adrenomedullin in heart failure. Peptides 22: 1841-1850, 2001.
13. Jougasaki M, Heublein DM, Sandberg SM, Burnett JC Jr.:
    Attenuated natriuretic actions of adrenomedullin in experimental heart failure. J Card Fail 7: 75-83, 2001.
14. Jougasaki M, Burnett JC Jr.:
    Continuing insights into the heart as an endocrine organ: adrenomedullin and cardiac fibroblasts. Cardiovasc Res 49: 695-696, 2001.
15. Jougasaki M, Burnett JC Jr.:
    Adrenomedullin as a renal regulator peptide. Nephrol Dial Transplant 15: 293-295, 2000.
16. Jougasaki M, Tachibana I, Luchner A, Leskinen H, Redfield MM, Burnett JC Jr.:
    Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. Circulation 101: 14-17, 2000.
17. Jougasaki M, Burnett JC Jr.:
    Adrenomedullin: Potential in physiology and pathophysiology. Life Sci 66: 855-872, 2000.
18. Jougasaki M, Schirger JA, Simari RD, Burnett JC Jr.:
    Autocrine Role for the Endothelin-B Receptor in the Secretion of Adrenomedullin. Hypertension 32: 917-922, 1998.
19. Jougasaki M, Stevens TL, Borgeson DD, Luchner A, Redfield MM, Burnett JC Jr.:
    Adrenomedullin in experimental congestive heart failure: Cardiorenal activation. Am J Physiol 273: R1392-1399, 1997.
20. Jougasaki M, Aarhus LL, Heublein DM, Sandberg SM, Burnett JC Jr.:
    Role of prostaglandins and renal nerves in the renal actions of adrenomedullin. Am J Physiol 272: F260-F266, 1997.
21. Jougasaki M, Rodeheffer RJ, Redfield MM, Yamamoto K, Wei C-M, McKinley LJ, Burnett JC Jr.:
    Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 97: 2370-2376, 1996.
22. Jougasaki M, Wei C-M, McKinley LJ, Burnett JC Jr.:
    Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 92: 286-289, 1995.
23. Jougasaki M, Wei C-M, Heublein DM, Sandberg SM, Burnett JC Jr.:
    Immunohistochemical localization of adrenomedullin in canine heart and aorta. Peptides 16: 773-775, 1995.
24. Jougasaki M, Wei C-M, Aarhus LL, Heublein DM, Sandberg SM, Burnett JC Jr.:
    Renal Localization and actions of adrenomedullin: a natriuretic peptide. Am J Physiol 268: F657-F633, 1995.
25. Jougasaki M, Kugiyama K, Saito Y, Nakao K, Imura H, Yasue H:
    Suppression of endothelin-1 secretion by lysophosphatidylcholine in oxidized low density lipoprotein in cultured vascular endothelial cells. Circ Res 71:
26. Jougasaki M, Yasue H, Mukoyama M, Nakao K, Takahashi K:
    Appearance of atrial natriuretic peptide in the ventricles in patients with myocardial infarction. Am Heart J 119: 92-96, 1990.
27. Jougasaki M, Yasue H, Takahashi K:
    Perivascular nerve lesion of the coronary artery involved in spasm in a patient with variant angina. Pathology 21: 304-307, 1989.
28. Jougasaki M, Yasue H, Okumura K, Mukoyama M, Saito Y, Nakao K, Takahashi K:
    Atrial natriuretic peptide in the ventricles in patients with dilated cardiomyopathy and human foetuses. Histochem J 21: 715-720, 1989.

共同開発・研究

• 糖尿病患者におけるDPP-4阻害薬のスイッチングが生理活性物質に及ぼす影響の研究

主な研究費取得状況

城ヶ崎倫久

分野サイト